natgillin/translations-raw huggingface dataset:
EU/1/09/574/024 280 film-coated tablets (multipack, 20 cartons of 14 tablets) EU/1/09/574/023 280 film-coated tablets (multipack, 4 cartons of 70 tablets) (unit dose) 
EU/1/09/574/024 280 filmom obloženih tableta (višestruko pakiranje, 20 kutija od 14 tableta) EU/1/09/574/023 280 filmom obloženih tableta (višestruko pakiranje, 4 kutije od 70 tableta)
• feeling unwell 
• loše osjećanje
No dose adjustment of Dafiro HCT is required for patients with mild to moderate renal impairment (GFR ≥30 ml/min/1.73 m 
U bolesnika s blagim do umjerenim oštećenjem bubrega (GFR >30 ml/min/1,73 m 2) dozu Dafiro
Constipation 
Konstipacija
Very common (may affect more than 1 in 10 people): 
Vrlo često (mogu se javiti u do1 na 10 osoba):
EU (MA) number Invented name 
EU broj odobrenja Izmišljeno ime
Pemetrexed Lilly is a cancer medicine used to treat two types of lung cancer: 
Pemetrexed Lilly je lijek protiv raka koji se koristi za liječenje dva tipa raka pluća:
This means that Pemetrexed Lilly is similar to a ‘reference medicine' already authorised in the European Union (EU) called Alimta. 
To znači da je Pemetrexed Lilly sličan „referentnom lijeku” koji je već odobren u Europskoj uniji (EU) pod nazivom Alimta.
In the body, pemetrexed is converted into an active form that blocks the activity of the enzymes that are involved in producing ‘nucleotides' (the building blocks of DNA and RNA, the genetic material of cells). 
U tijelu pemetreksed se konvertira u djelatni oblik koji blokira djelovanje enzima koji su uključeni u proizvodnju „nukleotida” (stanica koje grade DNK i RNK, genetski materijal stanica).
The medicine can only be obtained with a prescription and should only be given under the supervision of a doctor who is qualified in the use of chemotherapy. 
Ovaj se lijek izdaje samo na liječnički recept i smije se primjenjivati samo pod nadzorom liječnika koji ima iskustva u primjeni kemoterapije.
Because Pemetrexed Lilly is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's. 
Budući da je Pemetrexed Lilly generički lijek, smatra se da su njegovi koristi i rizici isti kao i oni referentnog lijeka.
Pemetrexed Lilly is a ‘generic medicine'. 
Pemetrexed Lilly je „generički lijek”.
The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Pemetrexed Lilly has been shown to be comparable to Alimta. 
Odbor za lijekove za primjenu kod ljudi (CHMP) pri Agenciji zaključio je kako je, u skladu s preduvjetima EU-a, potvrđeno da je lijek Pemetrexed Lilly usporediv s lijekom Alimta.
This is a summary of the European public assessment report (EPAR) for Pemetrexed Lilly. 
Ovo je sažetak europskoga javnog izvješća o ocjeni dokumentacije o lijeku (EPAR) za lijek Pemetrexed Lilly.
What measures are being taken to ensure the safe and effective use of Pemetrexed Lilly? 
Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Pemetrexed Lilly?
For practical information about using Pemetrexed Lilly, patients should read the package leaflet or contact their doctor or pharmacist. 
Praktične informacije o primjeni lijeka Pemetrexed Lilly bolesnici trebaju pročitati u uputi o lijeku, odnosno obratiti se svom liječniku ili ljekarniku.
A risk management plan has been developed to ensure that Pemetrexed Lilly is used as safely as possible. 
Pripremljen je plan upravljanja rizikom kako bi se osigurala što sigurnija primjena lijeka Pemetrexed Lilly.
Pemetrexed Lilly is available as a powder that is made up into a solution for infusion (drip) into a vein. 
Pemetrexed Lilly dostupan je kao prašak koji se koristi za pripremu otopine za infuziju (drip) u venu.
No additional studies were needed as Pemetrexed Lilly is a generic medicine that is given by infusion and contains the same active substance as the reference medicine, Alimta. 
Nisu bila potrebna dodatna ispitivanja jer je Pemetrexed Lilly generički lijek koji se daje infuzijom i sadrži istu djelatnu tvar kao i referentni lijek Alimta.
It is not intended to provide practical advice on how to use Pemetrexed Lilly. 
Svrha sažetka nije davati praktične savjete o primjeni lijeka Pemetrexed Lilly.
The full EPAR and risk management plan summary for Pemetrexed Lilly can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Cjelovito europsko javno izvješće o ocjeni dokumentacije o lijeku (EPAR) kao i sažetak plana upravljanja rizikom za lijek Pemetrexed Lilly nalaze se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports Više informacija o terapiji lijekom Pemetrexed Lilly pročitajte u uputi o lijeku (također dio EPAR-a), odnosno obratite se svom liječniku ili ljekarniku.
When Pemetrexed Lilly is given with cisplatin, an ‘antiemetic' medicine (to prevent vomiting) and fluids (to prevent dehydration) should also be given before or after the cisplatin dose. 
Ako se Pemetrexed Lilly primjenjuje s cisplatinom, prije ili nakon doze cisplatinom bolesniku također treba dati „antiemetik” (za sprječavanje povraćanja) i tekućinu (za sprječavanje dehidracije).
Other information about Pemetrexed Lilly 
Ostale informacije o lijeku Pemetrexed Lilly
What is Pemetrexed Lilly and what is it used for? 
Što je Pemetrexed Lilly i za što se koristi?
What are the benefits and risks of Pemetrexed Lilly? 
Koje su koristi i rizici lijeka Pemetrexed Lilly?
To reduce side effects, patients should take a corticosteroid (a type of medicine that reduces inflammation) and folic acid (a type of vitamin), and receive injections of vitamin B12 during treatment with Pemetrexed Lilly. 
Kako bi se ublažile nuspojave lijeka, bolesnici tijekom terapije lijekom Pemetrexed Lilly trebaju uzimati kortikosteroid (tip lijeka koji smanjuje upalu) i folnu kiselinu (tip vitamina) te primati injekcije vitamina B12.
Pemetrexed Lilly pemetrexed 
Pemetrexed Lilly pemetreksed
The Committee recommended that Pemetrexed Lilly be approved for use in the EU. 
Odbor je preporučio izdavanje odobrenja za stavljanje u promet lijeka Pemetrexed Lilly u EU-u.
Why is Pemetrexed Lilly approved? 
Zašto je Pemetrexed Lilly odobren?
The active substance in Pemetrexed Lilly, pemetrexed, is a cytotoxic medicine (a medicine that kills cells that are dividing, such as cancer cells), which belongs to the group ‘antimetabolites'. 
Djelatna tvar lijeka Pemetrexed Lilly, pemetreksed, citotoksičan je lijek (lijek koji uzrokuje smrt stanica koje se dijele, kao što su stanice karcinoma), a ubraja se u grupu „antimetabolita”.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Pemetrexed Lilly, including the appropriate precautions to be followed by healthcare professionals and patients. 
Lilly nalaze se sigurnosne informacije, uključujući odgovarajuće mjere opreza kojih se zdravstveni djelatnici i bolesnici trebaju pridržavati.
How is Pemetrexed Lilly used? 
Kako se Pemetrexed Lilly koristi?
Pemetrexed Lilly contains the active substance pemetrexed. 
Pemetrexed Lilly sadrži djelatnu tvar pemetreksed.
How has Pemetrexed Lilly been studied? 
Kako je Pemetrexed Lilly ispitivan?
Therefore, the CHMP's view was that, as for Alimta, the benefit outweighs the identified risk. 
Stoga je stav CHMP-a da u pogledu lijeka Pemetrexed Lilly, kao i kod lijeka Alimta, koristi nadmašuju utvrđene rizike.
How does Pemetrexed Lilly work? 
Kako djeluje Pemetrexed Lilly?
Patients are advised of the following: 
Bolesnicima se savjetuje sljedeće:
Contact our press officers Monika Benstetter or Martin Harvey 
Obratite se našim dužnosnicima za tisak Monika Benstetter ili Martin Harvey
Diacerein-containing medicines are taken by mouth and are currently authorised in the following EU Member States: Austria, Czech Republic, France, Greece, Italy, Portugal, Slovakia and Spain. 
Lijekovi koji sadrže diacerein uzimaju se kroz usta i trenutno su odobreni u sljedećim državama članicama EU-a: Austrija, Češka Republika, Francuska, Grčka, Italija, Portugal, Slovačka i Španjolska.
1 The CMDh is a medicines regulatory body representing the European Union (EU) Member States 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
1 CMDh je regulatorno tijelo za lijekove koje predstavlja države članice Europske unije (EU) 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
• Due to the risks associated with severe diarrhoea: 
• Zbog rizika povezanih s teškim proljevom:
The review of diacerein-containing medicines was initiated on 29 November 2012 at the request of the French medicines agency under Article 31 of Directive 2001/83/EC. 
Procjena lijekova koji sadrže diacerein započela je 29. studenog 2012. godine na zahtjev francuske Agencije za lijekove u skladu s člankom 31. Direktive 2001/83/EZ.
4 September 2014 EMA/544268/2014 
EMA/544268/2014
Tel. +44 (0)20 7418 8427 E-mail: press@ema.europa.eu 
Telefon +44 (0)20 3660 8427 E-pošta: press@ema.europa.eu
to 4 weeks, after which the recommended dose is 50 mg twice a day. 
2 do 4 tjedna nakon čega preporučena doza iznosi 50 mg dva puta na dan.
Contact your doctor if you have symptoms of liver problems. 
Obratite se svom liječniku ako imate simptome problema s jetrom.
The first beneficial effects of diacerein in these studies were seen after 2 to 4 weeks of continuous use. 
Prvi korisni učinci diacerein u ovim ispitivanjima uočeni su nakon 2 do 4 tjedna neprekidne uporabe.
• If you have any questions about your treatment, please contact your doctor or pharmacist. 
• Ako imate pitanja o liječenju, obratite se svom liječniku ili ljekarniku.
In the majority of cases diacerein-induced diarrhoea started in the first weeks of treatment. 
U većini slučajeva proljev izazvan diacereinom započeo je u prvim tjednima terapije.
The recommendations are based on a review of available data on the efficacy and safety of diacerein. 
Preporuke se temelje na pregledu dostupnih podataka o djelotvornosti i sigurnosti diacereina.
• If you have diarrhoea while taking diacerein, stop taking your medicine and contact your doctor to discuss which other treatments you can take. 
• Ako imate proljev dok uzimate diacerein prekinite uzimati svoj lijek i obratite se svom liječniku kako biste raspravili koje druge lijekove možete uzimati.
Your doctor will monitor your liver function on a regular basis and advise about the symptoms of liver problems (such as pruritus 
Vaš liječnik će redovito nadzirati funkciju Vaše jetre i savjetovati Vas o simptomima problema s jetrom (kao što je pruritus
(itching) and jaundice). 
(svrbež) i žutica).
However, following re-examination, the PRAC considered additional proposals to manage diacerein's risks and was satisfied that with new restrictions diacerein's benefits would outweigh its risks. 
Međutim, nakon ponovne procjene, PRAC je razmatrao dodatne prijedloge za upravljanje rizicima diacereina i bio je zadovoljan što s novim ograničenjima koristi diacereina nadmašuju njegove rizike.
In clinical studies, around 0.5% of patients on diacerein had some kind of liver reaction, with most cases being mild, reversible increases in serum transaminases. 
U kliničkim ispitivanjima približno 0,5% bolesnika na diacereinu imalo je neku vrstu jetrene reakcije dok su najčešći slučajevi bili blagi, prolazni porasti u razinama serumskih transaminaza.
Due to the risks associated with severe diarrhoea, diacerein is no longer recommended in patients aged 65 years and above. 
Zbog rizika povezanih s teškim proljevom, diacerein se više ne preporučuje u bolesnika u dobi od 65 godina i više.
The PRAC's final recommendations were sent to the Co-ordination Group for Mutual Recognition and Decentralised Procedures - Human (CMDh), which endorsed the recommendations and adopted a position by majority vote. 
Konačne preporuke PRAC-a poslane su Koordinacijskoj skupini za međusobno prepoznavanje i decentralizirane postupke za humane lijekove (CMDh) koja je potvrdila preporuke i većinski usvojila stajalište.
The proportion of patients with diarrhoea in clinical trials ranged from 0% to 54.4%. 
Udio bolesnika s proljevom u kliničkom ispitivanju kretao se u rasponu od 0 do 54,4%.
Restrictions intended to limit risks of severe diarrhoea and effects on the liver 
Ograničenja su namijenjena za ograničavanje rizika od teškog proljeva i učinaka na jetru
The CMDh position was sent to the European Commission which endorsed it and issued an EU-wide legally binding decision on 4 September 2014. 
Mišljenje CMDh poslano je Europskoj komisiji koja ga je potvrdila i izdala konačnu, pravno obvezujuću odluku za EU 4. rujna 2014.
− diacerein is not recommended in patients aged 65 years or above. 
− diacerein se ne preporučuje kod bolesnika u dobi od 65 godina i više.
With regard to safety, loose stools or diarrhoea were the most frequently reported adverse events in clinical studies with diacerein at a dose of 100 mg per day. 
S obzirom na sigurnost, vodenaste stolice ili proljev bile su najčešće prijavljivanje nuspojave u kliničkim ispitivanjima s diacereinom pri dozi od 100 mg po danu.
On 19 March 2014, the Co-ordination Group for Mutual Recognition and Decentralised ProceduresHuman (CMDh)1 endorsed recommendations to restrict the use of diacerein-containing medicines in order to manage the risks of severe diarrhoea and effects on the liver. 
Koordinacijska skupina za međusobno prepoznavanje i decentralizirane postupke za humane lijekove (CMDh) 19. ožujka 2014. godine1 potvrdila je preporuke za ograničavanje uporabe lijekova koji sadrže diacerein kako bi se upravljalo rizicima od teškog proljeva i učinaka na jetru.
Doctors should be monitoring their patients for early signs of liver problems and advising them how to recognise early symptoms. 
Liječnici trebaju nadzirati svoje bolesnike na rane znakove problema s jetrom i savjetovati ih kako prepoznati rane simptome.
As the CMDh position on diacerein was adopted by majority vote, it was sent to the European Commission which endorsed it and issued a final legally binding decision valid throughout the European Union (EU) on 4 September 2014. 
S obzirom da je većina usvojila stajalište CMDh o diacereinu, isto je poslano u Europsku komisiju koja ga je preporučila i izdala konačnu, pravno obvezujuću odluku koja vrijedi širom Europske unije (EU) od 4. rujna 2014.
It works by blocking the actions of interleukin-1 beta, a protein involved in the inflammation and destruction of cartilage that play a role in the development of symptoms of degenerative joint diseases such as osteoarthritis. 
Djeluje blokadom djelovanja interleukina1 beta, proteina koji je uključen u upalu i razaranje hrskavice koja igra ulogu u razvoju simptoma degenerativne bolesti zglobova poput osteoartritisa.
Doctors should also note that, based on available data, the use of diacerein is to be limited to treating symptoms of osteoarthritis affecting the hip or knee. 
Liječnici također trebaju imati na umu, a na temelju dostupnih podataka, da uporabu diacereina treba ograničiti kod liječenja simptoma osteoartritisa koji utječe na kuk ili koljeno.
Efficacy in the symptomatic treatment of osteoarthritis of the hip or knee was shown in published studies where diacerein was superior to placebo in relieving pain1-5. 
Djelotvornost u simptomatskom liječenju osteoartritisa kuka ili koljena dokazana je u objavljenim ispitivanjima gdje je diacerein bio superioran placebu u olakšavanju boli1-5.
These recommendations are based on the review of the benefits and risks of diacerein conducted by the EMA's Pharmacovigilance and Risk Assessment Committee (PRAC) and follow concerns raised by the French medicines agency (ANSM) about diacerein's gastro-intestinal and liver effects. 
Te se preporuke temelje na procjeni koristi i rizika diacereina koja je provedena od strane Odbora Europske agencije za lijekove za ocjenu rizika u farmakovigilanciji te slijede bojazni koje je iznijela Francuska agencija za lijekove (ANSM) o učincima diacereina na jetru i probavni sustav.
− it is advisable to start treatment with half the normal dose (i.e. 50 mg per day) for the first 2 
− savjetuje se da započnete liječenje polovicom normalne doze (tj. 50 mg na dan) tijekom prvih
• If you are taking diacerein and you are 65 years or above, contact your doctor to discuss your treatment. 
• Ako uzimate diacerein i ako ste stari 65 godina ili više obratite se svom liječniku kako biste raspravili svoje liječenje.
• Diacerein should only be used to treat symptoms of osteoarthritis of the hip or knee and it is not recommended for rapidly progressive hip osteoarthritis. 
• Diacerein se smije koristiti samo za liječenje simptoma osteoartritisa kuka i koljena i ne preporučuje se za rapidno progresivni osteoartritis kuka.
• You should not take diacerein if you have or have had liver problems. 
• Ne smijete uzimati diacerein ako imate ili ste imali probleme s jetrom.
In addition, diacerein-containing medicines must now not be used in any patient with liver disease or a history of liver disease, and doctors should be monitoring their patients for early signs of liver problems. 
Pored toga, lijekovi koji sadrže diacerein ne smiju se sada koristiti kod bilo kojeg bolesnika s bolešću jetre ili anamnezom bolesti jetre i liječnici moraju nadzirati svoje bolesnike na rane znakove problema s jetrom.
The proportion of patients who develop drug-induced liver injury following treatment with diacerein is estimated to be 0.03%. 
Udio bolesnika koji razvijaju jatrogenu ozljedu jetre nakon liječenja diacereinom procjenjuje se na 0,03%.
The CMDh endorsed the PRAC's final recommendations to address these concerns and ensure that diacerein's benefits continue to outweigh its known risks. 
CMDh potvrdi je konačne preporuke PRAC-a za rješavanje tih bojazni i daljnje osiguravanje da će koristi diacereina nadmašiti njegove poznate rizike.
Following an EU-wide review of diacerein, its use has been restricted in order to minimise the risks of severe diarrhoea and liver problems. 
Nakon procjene diacereina širom Europske unije njegova je uporaba ograničena kako bi se smanjili rizici od teškog proljeva i problem s jetrom.
In November 2013, the PRAC initially recommended the suspension of the marketing authorisations for diacerein-containing medicines. 
PRAC je stoga prvotno preporučio suspenziju odobrenja za stavljanje u promet za lijekove koji sadrže diacerein.
Pelletier JP, Yaron M, Haraoui B, Cohen P, Nahir M A, Choquette D, et al. Efficacy and Safety of Diacerein in Osteoarthritis of the Knee. 
4. Pelletier JP, Yaron M, Haraoui B, Cohen P, Nahir M A, Choquette D, et al.
Treatment should only be started by doctors experienced in treating osteoarthritis. 
Liječenje smiju započeti samo liječnici iskusni u liječenju osteoartritisa.
• Diacerein should only be used for treating symptoms of osteoarthritis affecting the hip or knee. 
• diacerein treba koristiti samo za liječenje simptoma osteoartritisa koji zahvaća kuk ili koljeno.
− treatment should be stopped if diarrhoea occurs. 
− liječenje treba prekinuti u slučaju pojave proljeva.
• Treatment should only be started by doctors experienced in treating osteoarthritis. 
• Liječenje smiju započeti samo liječnici iskusni u liječenju osteoartritisa.
• Diacerein must not be used in any patient with liver disease or a history of liver disease. 
• Diacerein se ne smije koristiti ni u jednog bolesnika s bolešću jetre ili anamnezom bolesti jetre.
Elevated serum liver enzymes and cases of symptomatic acute hepatic injury have been reported in the post-marketing phase with diacerein. 
Povišene razine jetrenih enzima u serumu i slučajevi simptomatske ozljede jetre prijavljeni su s diacereinom kao suspektnim lijekom nakon stavljanja lijeka u promet.
The review of diacerein was conducted by the Pharmacovigilance Risk Assessment Committee (PRAC). 
Odbor za ocjenu rizika u farmakovigilanciji (PRAC) proveo je pregled podataka za diacerein.
Diacerein is a medicine used to treat joint diseases such as osteoarthritis (swelling and pain in the joints). 
Diacerein je lijek koji se koristi za liječenje bolesti zglobova poput osteoartritisa (oticanja i boli u zglobovima).
Diacerein is a slow-acting medicine of the class ‘anthraquinones' used to treat joint diseases such as osteoarthritis (swelling and pain in the joints). 
Diacerein je lijek sporog djelovanja klase „antrakinona” koji se koristi za liječenje bolesti zglobova poput osteoartritisa (oticanja i boli u zglobovima).
It is also advised that patients start treatment on half the normal dose (i.e. 50 mg daily instead of 100 mg) and should stop taking diacerein if diarrhoea occurs. 
50 mg dnevno umjesto 100 mg), a u slučaju proljeva treba prestati uzimati diacerein.
1994 Apr;37(4):529-36. 
Diacerhein in the treatment of osteoarthritis of the hip. Arthritis Rheum. 1994 Apr;37(4):529-36.
Nguyen M, Dougados M, Berdah L, Amor B. Diacerhein in the treatment of osteoarthritis of the hip. 
5. Nguyen M, Dougados M, Berdah L, Amor B.
Singh K, Sharma R, Rai J. Diacerein as adjuvant to diclofenac sodium in osteoarthritis knee. 
Diacerein as adjuvant to diclofenac sodium in osteoarthritis knee.
Lequesne M, Berdah L, Gérentes I. Efficacy and Safety of Diacerein for the treatment of Knee and Hip Osteoarthritis [Efficacité et tolérance de la diacerhéine dans le traitment de la gonarthrose et de la coxarthrose]. 
[Efficacité et tolérance de la diacerhéine dans le traitment de la gonarthrose et de la coxarthrose].
(Invented)name Strength Pharmaceutical Form 
Farmaceutski oblik
Pack size l t o r 
Veličina pakovanja vrećica (papir/folija/Bar ex® laminat)
The full EPAR for Bortezomib Sun can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Cjeloviti EPAR za lijek Bortezomib Sun nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The recommended dose is calculated using the patient's height and weight). 
Preporučena doza izračunava se na osnovi visine i tjelesne težine bolesnika.
If a patient develops severe side effects, treatment must be discontinued, delayed or the dose adjusted. 
Ako se u bolesnika pojave ozbiljne nuspojave, liječenje se mora prekinuti, odgoditi ili se doza mora prilagoditi.
At least 72 hours must pass between two doses of Bortezomib Sun. 
Mora proći najmanje 72 sata između dvije uzastopne doze lijeka Bortezomib Sun.
Patients with moderate or severe liver problems should be treated with lower doses. 
Bolesnici s umjerenim ili ozbiljnim problemima jetre trebaju se liječiti manjim dozama.
This means that Bortezomib Sun is similar to a ‘reference medicine' already authorised in the European Union (EU) called Velcade. 
To znači da je Bortezomib Sun sličan „referentnom lijeku” koji je već odobren u Europskoj uniji (EU) pod nazivom Velcade.
It blocks proteasome, which is a system in cells that breaks down proteins that are no longer needed. 
Ta tvar onemogućuje djelovanje proteazoma, sustava unutar stanica koji razgrađuje proteine koji više nisu potrebni.
The medicine can only be obtained with a prescription and treatment should only be started and given under the supervision of a doctor who has experience in the use of cancer chemotherapy. 
Lijek se izdaje samo na liječnički recept, a liječenje se mora započeti i provoditi pod nadzorom liječnika specijalista s iskustvom u primjeni kemoterapije.
When given into a vein, the solution is injected through a catheter (a thin sterile tube). 
Kada se primjenjuje u venu, otopina se injicira kroz kateter (tanka sterilna cjevčica).
Blocking the proteasome system causes the cell to die. 
Onemogućivanje djelovanja sustava proteazoma uzrokuje smrt stanica.
Bortezomib Sun must not be given by other routes. 
Lijek Bortezomib Sun ne smije se davati drugim putovima.
When injected under the skin, it is given in the thigh or abdomen (tummy). 
U slučaju ubrizgavanja ispod kože, lijek se daje u bedro ili abdomen (trbuh).
• adults whose disease is getting worse after at least one other treatment and who have already had, or cannot undergo, blood stem-cell transplantation. 
• u odraslih osoba čija se bolest pogoršava nakon najmanje jednog liječenja i koje su već bile podvrgnute, ili se ne mogu podvrgnuti, transplantaciji hematopoetskih matičnih stanica.